Journal article
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
NC Tebbutt, F Murphy, D Zannino, K Wilson, MM Cummins, E Abdi, AH Strickland, RM Lowenthal, G Marx, C Karapetis, J Shannon, D Goldstein, SS Nayagam, R Blum, L Chantrill, RJ Simes, TJ Price
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2011
Abstract
BACKGROUND: Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab. PATIENTS AND METHODS: We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patients with metastatic colorectal cancer in the MAX (Mitomycin, Avastin, Xeloda) trial of capecitabine monotherapy versus capecitabine with bevacizumab with or without mitomycin C. RESULTS: Bevacizumab-treated patients had 12 grade 3, 4, or 5 ATEs (3.8% incidence). ATEs occurred in 2.1% of patients >65 yea..
View full abstractGrants
Funding Acknowledgements
Roche Products Pty Ltd (Australia); Roche Products Ltd (UK).NCT, CK, and TJP have participated in advisory boards for Roche. The National Health and Medical Research Council Clinical Trials Centre, University of Sydney (RJS), has received research grants from Roche for the MAX trial. No other potential conflicts have been reported.